AU Patent

AU2019346543A1 — Composition and use for the treatment of Parkinson's disease and related disorders

Assigned to Chase Therapeutics Corp · Expires 2021-05-20 · 5y expired

What this patent protects

The present invention provides a pharmaceutical combination comprising an inhibitor of dopamine agonist adverse effects and a dopamine agonist, for treating Parkinson's disease and Parkinson's disease-related disorders.

USPTO Abstract

The present invention provides a pharmaceutical combination comprising an inhibitor of dopamine agonist adverse effects and a dopamine agonist, for treating Parkinson's disease and Parkinson's disease-related disorders.

Drugs covered by this patent

apomorphine-hydrochloride (APOMORPHINE HYDROCHLORIDE)

Patent Metadata

Patent number: AU2019346543A1
Jurisdiction: AU
Classification: —
Expires: 2021-05-20
Drug substance claim: No
Drug product claim: No
Assignee: Chase Therapeutics Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.